Business Of Biotech

AI-Driven Biologics With Fountain Therapeutics' William Greene, M.D

Matt Pillar

We love to hear from our listeners. Send us a message.

With its hypothesis-free, target-free, AI-driven drug discovery platform, Fountain Therapeutics is turning the traditional drug discovery pathway on its ear to address a variety of age-related disease. On this week's episode of the Business of Biotech, Fountain CEO William Greene, M.D. joins us to discuss the approach, its rationale,  and how the company is applying substantial support from the likes of Eli Lilly, Alexandria Venture Investments, R42 Group,  Khosla Ventures, and Nan Fung Life Sciences.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com

Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/


People on this episode

Podcasts we love

Check out these other fine podcasts recommended by us, not an algorithm.